Great to see The University of Queensland's EARLY study underway, exploring how pre‑analytical factors—blood collection, storage temperatures, transport and time to processing—impact extracellular vesicle (EV) biomarker stability.

INOVIQ Ltd (ASX:IIQ) strongly supports this important exosome research. While EARLY doesn't assess the clinical performance of our EXO‑OC ovarian cancer screening test, it will deliver important insights for future EV‑based population screening.

Congratulations to Professor Carlos Salomon and the UQ team on launching this impactful study.